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Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune 
disease characterized by autoantibody production, inflamma-
tion, and tissue damage in multiple organs resulting from the 
activation of numerous proinflammatory pathways (1, 2). Clin-
ical manifestations vary widely among patients and commonly 
include rash, arthritis, and nephritis, but the central nervous sys-
tem and other major organ systems can also be affected (3).
Therapies used to treat SLE, such as antimalarials, corticoste-
roids, and immunosuppressive drugs, are only partially effective 
and have a wide range of toxicities (4–7). Thus, there is an unmet 
need for more efficacious and safer therapies that specifically 
target critical pathways in SLE. Type I IFN (IFN-I) plays a major 
role in the pathogenesis of SLE (8, 9), and several approaches for 
targeting the IFN-I pathway have been explored in clinical trials. 
These include neutralizing mAbs against subtypes of IFN-I (10). 
Positive results from phase II SLE clinical trials with anti–IFN-α 
mAb (sifalimumab) and anti–IFN-αβ receptor (anifrolumab) sup-
port the pathogenic role of the IFN-I pathway in SLE (11, 12).
Plasmacytoid DCs (pDCs) are a specialized population of 
bone marrow–derived cells that synthesize large amounts of IFN-I 
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single administration of BIIB059 in HV and 
patients with SLE (parts 1 and 2, respectively). 
Part 1 was dose ascending and consisted of 6 
cohorts of HV receiving a single i.v. infusion of 
BIIB059, with doses ranging from 0.05 mg/kg 
to 20 mg/kg (Figure 1 and Supplemental Table 
1). An additional cohort of HV (cohort 7) was 
enrolled to receive a single fixed s.c. dose of 50 
mg BIIB059 to determine the relative bioavail-
ability of s.c. compared with i.v. administration 
(Figure 1 and Supplemental Table 1). In part 2 
of the study, a single i.v. dose of BIIB059 (20 
mg/kg) was evaluated in adult patients with 
SLE and active cutaneous lupus erythematosus 
(CLE), as defined by the presence of acute, sub-
acute, and/or chronic cutaneous lupus at the 
time of screening and randomization (cohort 
8). Patients with SLE were diagnosed according 
to the 1997 ACR criteria for SLE diagnosis (Sup-
plemental Table 3). The dose level in cohort 8 
was selected to match the highest evaluated 
and tolerable dose from part 1 (Figure 1 and 
Supplemental Table 1). In parts 1 and 2, the 
demographic and baseline characteristics were 
similar between the pooled placebo group and the pooled BIIB059 
group (Tables 1 and 2), and all patients with SLE enrolled had mild 
to moderate disease activity and active skin manifestations, as 
measured by the Systemic Lupus Erythematosus Disease Activity 
Index 2000 (SLEDAI-2K) (35) and Cutaneous Lupus Erythema-
tosus Disease Area and Severity Index Activity (CLASI-A) scoring 
(36, 37) (Tables 1 and 2 and Supplemental Results).
In part 1, single-dose administration of BIIB059 was well tol-
erated across all dose levels and treatment groups. Most of the 
adverse events (AEs) were mild to moderate in severity, and there 
were no serious AEs (SAEs). The most commonly reported AE 
was upper respiratory tract infection in 3 HV treated with BIIB059 
(Supplemental Table 2). One event of headache was considered 
in response to ligands that engage endosomal TLR7 or TLR9 
(13). pDCs are also thought to be the major producers of IFN-I in 
response to immune complexes (13, 14). In SLE, pDC numbers 
decrease in the blood and accumulate in affected organs, such as 
lesional skin or kidneys (15–23). The accumulation of pDCs in skin 
lesions or kidneys, together with their ability to produce copious 
amounts of IFN-I, make pDCs an appealing target for therapeu-
tic intervention in SLE. Depletion of pDCs has been shown to be 
beneficial in preclinical mouse models of TLR7/TLR9-dependent 
cutaneous diseases as well as in lupus nephritis, which further sup-
ports the pathogenic potential of pDCs (24–27).
BIIB059 is a humanized IgG1 mAb that specifically recogniz-
es blood DC antigen 2 (BDCA2), which is uniquely expressed on 
the surface of human pDCs (28, 29). BIIB059 binding to BDCA2 
results in its rapid internalization from the cell surface of human 
pDCs and the subsequent inhibition of IFN-I (all subtypes), cyto-
kine, and chemokine production by pDCs (28, 30–34). In this 
first-in-human phase 1 study (NCT02106897), the safety, tolera-
bility, and pharmacokinetics (PK) of single doses of BIIB059 were 
assessed in both healthy volunteers (HV) and a cohort of patients 
with SLE and active skin disease. Effects on pharmacodynamic 
(PD) markers and clinical activity were evaluated.
Results
Safety, tolerability, and immunogenicity after administration of 
BIIB059 in HV and patients with SLE. First-in-human evaluation of 
BIIB059 was conducted in a 3-part phase 1 study (NCT02106897): 
single ascending doses in HV (part 1), a single dose in patients with 
SLE (part 2), and multiple ascending doses in HV and patients 
with SLE (part 3) (Supplemental Figure 1; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
JCI124466DS1). This study reports the safety, tolerability, PK, 
PD, immunogenicity, and proof of biological activity following a 
Figure 1. Study design. Single ascending dose in the HV cohorts and single dose in the SLE cohort. 
Table 1. Baseline characteristics of study participants:  
study part 1, HV
Characteristic Pooled placebo 
(n = 16)




Completed study, n (%) 14 (87.5) 36 (94.7) 50 (92.6)
Age, yr, mean (SD) 38.1 (11.7) 34.4 (10.6) 35.5 (10.9)
Female sex, n (%) 6 (38) 17 (45) 23 (43)
Race, n (%)
Black/African American 4 (25) 12 (32) 16 (30)
White 10 (63) 22 (58) 32 (59)
Asian – 1 (3) 1 (2)
American Indian/Alaskan native – 1 (3) 1 (2)
Other 2 (13) 2 (5) 4 (7)
Body weight, kg, mean (SD) 79.9 (13.3) 73.3 (10.6) 75.2 (11.7)
Body mass index, kg/m2, mean (SD) 25.9 (2.9) 24.1 (2.9) 24.7 (3.0)
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(Supplemental Figure 4 and data not shown). There were no clini-
cally significant changes in physical examinations or ECG, and no 
dose-dependent patterns of abnormalities were observed. None 
of the study participants discontinued the study treatment owing 
to AEs in either part 1 or part 2.
Overall, 6 of 38 HV and no patients with SLE receiving 
BIIB059 tested positive for anti-BIIB059 binding Ab. Of these 
responses, 4 were transient responses and 2 were persistent, 
low-titer responses (data not shown). These antidrug Ab did not 
affect BIIB059 exposure (PK) or PD, and there was no association 
with safety events.
PK and PD analyses in HV and patients with SLE. Following 
a single 1-hour i.v. infusion of BIIB059 (0.05–20 mg/kg) in HV, 
serum BIIB059 Cmax and total AUC from time 0 extrapolated to 
infinity (AUC∞) increased with dose (Figure 2A and Table 4). The 
deviation from dose proportionality at low-dose levels was driv-
en by target-mediated clearance of BIIB059 (<1 mg/kg). Serum 
BIIB059 declined multiexponentially, with mean t1/2 values 
generally increasing with dose, ranging from approximately 3.5 
days (0.05 mg/kg) to 27 days (10 mg/kg and 20 mg/kg) (Table 
4). Following single s.c. administration of 50 mg BIIB059 to HV, 
BIIB059 was slowly absorbed, with a tmax of approximately 6 days 
and a mean terminal t1/2 of 12 days. In patients with SLE, a single 
i.v. infusion of 20 mg/kg BIIB059 achieved maximum serum 
concentration at a median tmax of approximately 2 hours and was 
eliminated with a mean terminal t1/2 of 18 days. BIIB059 exposure 
(AUC) was approximately 40% lower in patients with SLE com-
pared with HV at the same dose (Figure 2B and Table 4).
BIIB059 exposure leads to rapid internalization of BDCA2 on 
human pDCs in vitro and in cynomolgus pDCs in vivo (28). In this 
clinical study, BDCA2 internalization on pDCs was evaluated as 
both a measure of target engagement and of PD response using a 
flow cytometric assay. Specifically, the assay incorporated a non-
crossblocking Ab that recognizes an epitope of BDCA2 that is differ-
ent from that of BIIB059. Reductions in BDCA2 levels on pDCs com-
pared with baseline were observed in all BIIB059-treated patients, 
but not following placebo administration. More than 90% of surface 
BDCA2 on pDCs was internalized in HV and SLE subjects within 
1 hour to 2 days after BIIB059 administration (Figure 3, A and B). 
The duration of BDCA2 internalization was dose dependent, with 
BDCA2 on the surface of pDCs returning to baseline levels within 
a shorter period of time at lower doses compared with higher doses 
(Figure 3A). On average, the duration of BDCA2 internalization after 
related to BIIB059 in the 1 mg/kg group. In part 2, single-dose 
administration of BIIB059 in patients with SLE was well tolerat-
ed (Table 3). One patient experienced a total of 9 SAEs, the first 
starting on day 77 and the last occurring on day 150, after a single 
treatment with 20 mg/kg i.v BIIB059. All SAEs were thought to be 
unrelated to BIIB059 by the investigator (Supplemental Results). 
Most of the AEs were mild to moderate in severity (Table 3), and 
the most commonly reported AE was upper respiratory tract infec-
tion in 3 patients treated with BIIB059 (Supplemental Table 2). 
One treated patient developed herpes zoster on day 141, which 
was considered related to the study drug by the investigator and 
was moderate in severity in the 20 mg/kg group.
Sporadic out-of-range values were noted for hematology and 
blood chemistry parameters; however, no clinically significant 
differences between the treatments were observed. There were 
no relevant findings observed for vaccine titer data, immuno-
globulin levels, complement levels, immunophenotyping, WBC 
counts, and absolute differential counts in any part of the study 
Table 2. Baseline characteristics of study participants:  
study part 2, patients with SLE






Completed study, n (%) 3 (75) 8 (100) 11 (92)
Age, yr, mean (SD) 43.3 (13.3) 41.1 (12.6) 41.8 (12.3)
Female sex, n (%) 4 (100) 8 (100) 12 (100)
Race, n (%)
Black/African American 2 (50) 1 (13) 3 (25)
White 2 (50) 6 (75) 8 (67)
Asian 0 0 0
American Indian/Alaskan native 0 0 0
Other 0 1 (13) 1 (8)
Body weight, kg, mean (SD) 73.6 (14.5) 68.9 (9.8) 70.5 (11.2)
Body mass index, kg/m2, mean (SD) 27.0 (6.9) 24.6 (3.2) 25.4 (4.6)
CLE classification (A/S/C)A 0/2/2 4/1/3 4/3/5
CLASI-A score, mean (SD) 16.3 (19.2) 10.4 (5.4) 12.3 (11.3)
SLEDAI-2K score mean (SD) 7.5 (3.4) 5.9 (4.7) 6.4 (4.2 )
Antinuclear Ab, n (%) 4 (100) 8 (100) 12 (100)
Anti-dsDNA 0 1 (13) 1 (8)
Anti-Smith 0 2 (25) 2 (17)
Anti-SSA 2 (50) 7 (88) 9 (75)
Anti-SSB 0 1 (13) 1 (8)
Anti-RNP 2 (50) 5 (63) 7(58)
Concomitant medications, n (%)
AntimalarialsB 1 (25) 2 (25) 3 (25)
Azathioprine 0 0 0
Methotrexate 0 1 (13) 1 (8)
Topical steroids 0 0 0
Oral corticosteroidsC 0 2 (25) 1 (17)
AA, acute CLE; S, subacute CLE; C, chronic CLE including DLE. BAntimalarial 
medications include hydroxychloroquine or equivalent. COral corticosteroids 
include prednisone or equivalent. SSA, Sjögren’s syndrome antigen A; SSB, 
Sjögren’s syndrome antigen B; RNP, ribonucleoprotein.
Table 3. Safety summary: study part 2, patients with SLE
Subjects, n (%) Placebo BIIB059
Dosed 4 8
With any AE 3 (75) 7 (88)
Moderate event 2 (50) 4 (50)
Severe event 1 (25) 1 (13)
Related event 1 (25) 1 (13)
Serious event/related serious event 0/0 1 (13)
Discontinuation/withdrawal due to event 0/0 0/0
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suggest that BIIB059 administration leads to BDCA2 internaliza-
tion without a sustained decrease in pDC numbers.
IFN response markers in whole blood and lesional skin. Since 
BIIB059-mediated BDCA2 internalization is functionally linked 
to inhibition of IFN-I production by pDCs, we assessed whether 
BIIB059 modulated the activation of the IFN pathway in patients 
with SLE. To this end, we investigated the expression of IFN 
response genes (IRG) from whole blood (Supplemental Figure 3) 
and hallmark IFN response proteins in lesional skin.
IRG were initially selected on the basis of previously pub-
lished IRG data. IRG selection was further refined based on the 
separation of expression between HV and SLE subjects, the cor-
relations among genes, and expression in an internal SLE cohort 
(Supplemental Figure 3). Their expression was measured in 
whole blood at baseline and several time points after BIIB059 
administration using quantitative PCR. All enrolled patients 
with SLE showed elevated expression in IRG compared with HV 
at baseline (Supplemental Figure 3). Single doses of BIIB059 at 
20 mg/kg i.v. led to rapid, partial neutralization (~50%) of IRG 
expression within 24 hours after BIIB059 administration (Figure 
4, B and C) compared with placebo (Figure 4A). Since BIIB059 
treatment didn’t affect the immune cell composition in whole 
blood of treated patients, as measured by differential cell count 
(Supplemental Figure 4), changes in IRG likely reflect the spe-
a single injection of BIIB059 was 14 days at the lowest dose (0.05 
mg/kg) in HV, whereas at the highest dose (20 mg/kg), BDCA2 con-
tinued to be internalized in most subjects at the last time point tested 
(112 days) in HV (Figure 3A). Comparisons of individual exposure 
data and BDCA2 levels on pDC cell surfaces for all treated subjects 
indicated that circulating BIIB059 must drop below a threshold of 
approximately 1 μg/ml before BDCA2 on pDC cell surfaces starts 
returning to baseline levels (data not shown). Since the BIIB059 
exposure (AUC) was lower in patients with SLE compared with HV, 
BIIB059 serum concentration dropped below the 1 μg/ml threshold 
on days 84 and 112 in some patients, and therefore BDCA2 levels on 
pDCs started recovering at these time points (Figure 3B).
Internalization of BDCA2 correlated with circulating levels 
of BIIB059 in both HV (Figure 3C) and patients with SLE (Figure 
3D), establishing a PK/PD relationship in vivo.
Reduction from baseline in the number of circulating pDCs was 
observed following BIIB059 administration, even at the lowest dose 
level tested (Supplemental Figure 2). The observed reduction was 
transient, with approximately 50% recovery in average pDC num-
bers by week 2 in BIIB059-treated HV and patients with SLE (Sup-
plemental Figure 2, B–F). In the 20 mg/kg treatment groups (HV 
and SLE), recovery in pDC numbers was observed in the presence of 
more than 100 μg/ml of BIIB059 at week 2, when BDCA2 was still 
fully internalized on pDCs (Supplemental Figure 2G). These data 
Figure 2. BIIB059 PK profile in HV and a cohort of patients with SLE with active cutaneous lupus. BIIB059 serum levels were measured using ELISA. 
(A) PK of single ascending dose of BIIB059 in HV (n = 38) and (B) PK of 20 mg/kg BIIB059 in HV (black line) (n = 6) and patients with SLE (red line) (n = 8). 
Arithmetic mean values are represented. conc., concentrations.
Table 4. PK parameters
HV Patients with SLE
Variable, mean  
(% CV)
0.05 mg/kg  
i.v.
0.3 mg/kg  
i.v.
1 mg/kg  
i.v.
3 mg/kg  
i.v.
10 mg/kg  
i.v.
20 mg/kg  
i.v.
50 mg  
s.c.
20 mg/kg  
i.v.
AUCt, μg/ml/hr 119 (50.8) 1865 (36.8) 10246 (21.2) 30758 (30.2) 111535 (21.9) 225560 (17.8) 3013 (32.5) 158191.8 (36)
AUC∞, μg/ml/hr 229 (NC) 2188 (45.5) 11105 (21.3) 32056 (31.6) 121191 (21.1) 246903 (13.3) 3508 (27.5) 162499.4 (37)
Cmax, μg/ml 1.68 (9.8) 10.9 (25.4) 31.7 (11.7) 82.5 (12.1) 280 (23) 603 (10.6) 5.56 (16.1) 473 (31.6)
tmax, hours NA NA NA NA NA NA 144 NA
t1/2, days 3.5 (27) 8.5 (38.8) 16.8 (34) 18.6 (47.4) 27.3 (20.3) 27.2 (14.6) 11.8 (36.3) 18.1 (40.8)
CV, coevfficient of variation; NC, not calculated.
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to a robust and sustained inhibition of the IFN pathway in a fre-
quently involved organ (skin) in SLE and results additionally in 
partial neutralization of the IFN signature in the blood.
Correlation of cutaneous IFN response markers and CLASI-A 
score. In addition to assessing the impact of BIIB059 on the 
activation of the IFN pathway in blood and lesional skin, the 
activity of cutaneous disease was also determined using CLA-
SI-A scores at various time points after a single administration 
of BIIB059 (Figure 5). Patients were considered responders if 
they exhibited a CLASI-A score reduction from baseline (day 
–1) of at least 4 points at week 4 and/or week 12 after BIIB059 
treatment, which is consistent with the defined minimal clin-
ically important difference of CLASI-A (36, 37). Skin lesion 
adjudications were conducted to confirm both a lupus skin 
diagnosis and activity at baseline.
Six of eight patients with SLE receiving a single dose of 20 
mg/kg i.v. BIIB059 were considered responders on the basis 
of the CLASI-A reduction criteria (Figure 5B). Importantly, the 
patients who were CLASI-A responders also exhibited signif-
icant reductions in lesional skin MxA expression (Figure 5B). 
cific effect of BIIB059 on pDCs. Thus, these data confirm that 
pDC-derived IFN-I contributes to the IFN signature detected in 
the blood of patients with SLE.
PDCs have been shown to accumulate in the skin of patients 
with SLE, and they play an important role in disease pathogenesis 
(15, 16, 19, 21–23). Therefore, we sought to determine the impact 
of BIIB059 on the IFN-I response in active skin lesions within the 
SLE cohort. Skin biopsies from active lesions in 11 of 12 patients 
were evaluated at baseline (day –1) and week 4 for IFN-regulated 
proteins MxA (Figure 5, A and B) and IFITM3 (Supplemental Fig-
ure 5A) using immunohistochemistry on formalin-fixed 4 to 5 mm 
punch biopsies.
Marked reductions in MxA percentage area immunoreactivity 
were detected in 6 of 7 patients with SLE 4 weeks after BIIB059 
administration, with an average week 4 change from baseline of 
–70% for the BIIB059 cohort (Figure 5B). Although 2 of 4 patients 
from the placebo group exhibited a decrease in MxA percentage 
area compared with baseline, the mean week 4 change from base-
line was +12% for the placebo group (Figure 5A). Together, these 
data indicate that targeting BDCA2 on pDCs with BIIB059 leads 
Figure 3. BII059 demonstrates PK and PD correlations in both HV and a cohort of patients with SLE. (A and B) BDCA2 levels on pDCs as the median 
percentage change in BDCA2 levels normalized to baseline level in HV placebo (PBO) cohort (n = 16), HV BIIB059-treated cohort (n = 38), SLE PBO (n = 4), 
SLE BIIB059-treated cohort (n = 8). Fluorescent-labeled noncrossblocking anti-BDCA2 mAb (2D6) was used to label surface BDCA2 on the pDC population 
(CD123+ HLA-DR+) in whole blood using flow cytometry. (C and D) PK/PD relationship between BIIB059 serum concentrations (red triangles, left axis) and 
BDCA2 expression on pDCs (black squares, right axis, normalized to baseline levels). Panel C depicts a representative HV from the 3 mg/kg dose group  
(n = 6). Panel D depicts a representative patient with SLE (20 mg/kg) (n = 8).
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Improvement in CLASI-A correlated (ρ = 0.67) with reduction 
in MxA (Figure 5C), suggesting that the activity of the IFN 
pathway in the skin associates with clinical cutaneous disease 
activity. These data indicate that a reduction in MxA expres-
sion in lesional skin may serve as a robust surrogate biomarker 
for clinical efficacy.
The reductions in CLASI-A scores observed at week 4 were 
maintained at week 12 after BIIB059 treatment in 5 of 6 patients 
with SLE (Figure 5D). In contrast, 3 of 4 patients who received 
placebo failed to improve at both week 4 and week 12 (Figure 5, A 
and D). The precipitous decline in the CLASI-A score of placebo 
patient 1 measured at week 12 (Figure 5D) occurred after treat-
ment with parenteral methylprednisolone sodium succinate for 
hand pain administered at day 43 and prednisone treatment for 
arthritis on days 53–55. These data suggest that administration of 
a single dose of BIIB059 can lead to a sustained clinical benefit, at 
least up to 12 weeks.
Cutaneous MxA expression and histology. Given the decrease 
of the IFN response marker MxA in the lesional skin of patients 
with SLE after BIIB059 administration (Figure 5B and Figure 
6C), we sought to determine the degree of normalization of 
skin biomarkers in BIIB059-treated patients compared with 
HV. To this end, skin biopsies were collected from 8 HV, and 
the percentage of MxA-positive staining area in the epidermis 
was measured to establish the normal range (Figure 6). Six 
of seven patients in the BIIB059 treatment cohort displayed 
elevated baseline (day –1) MxA expression above the normal 
range, as determined in this population of 8 HV (Figure 6B). At 
week 4, BIIB059 treatment reduced MxA expression to the nor-
mal range in all but 1 patient (no. 12). This patient also demon-
strated no CLASI-A improvement (Figure 5, B and D). Three of 
four subjects in the placebo group had elevated baseline MxA 
expression in the skin comparable to that of the BIIB059 cohort 
and did not show any normalization at week 4 (Figure 6B).
Given the clinical and IFN biomarker responses observed 
in the BIIB059-treated group, we investigated the effects of 
BIIB059 treatment on the inflammatory cell infiltrates of lesion-
al skin. Skin biopsies were immunoreacted with anti-CD45, a 
pan-leukocyte marker, to detect immune cell infiltration (Figure 
6C). Cellular infiltrates were detected in most of the lesional skin 
biopsies of patients with SLE compared with healthy donors (Fig-
ure 6D). All CLASI-A responders with elevated baseline papillary 
dermal CD45+ immunoreactive area in the skin lesions (4 of 5 
patients) showed marked reductions in cellular infiltration upon 
treatment with BIIB059 (Figure 6D). In contrast, CD45+ immu-
noreactive area remained high in the placebo cohort.
Figure 4. Single dose of BIIB059 in patients with SLE dampens the expression of IRG in whole blood. Whole blood was collected in PAXgene Blood RNA 
Tubes. After RNA isolation, the expression of IRG was analyzed using the Fluidigm BioMark HD System. The ratio from baseline is shown for (A) place-
bo and (B) BIIB059 treatment of patients with SLE (C). Percentage change from baseline of the IFN score based on the 9 IRGs in individual patients.  
*Subject 1 initiated steroid treatment during the study.
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Figure 5. BIIB059 leads to decrease in the IFN response in the skin, which correlates with improve-
ment in CLASI-A score. (A and B) Skin biopsies from active lesions were evaluated at baseline (day –1) 
and week 4 after treatment with 20 mg/kg BIIB059 for MxA protein expression using quantitative IHC 
on formalin-fixed 4 to 5 mm punch biopsies. Representative photomicrographs and percentage area of 
epidermal MxA-positive immunoreactivity are shown for each patient in the placebo group (A) and the 
BIIB059-treated group (B). CLASI-A scores were evaluated at day –1, week 4, and week 12 after treatment 
for placebo-treated (A) and BIIB059-treated (B) patients with SLE. Response is defined as a 4 or more 
point reduction from baseline in CLASI-A score at week 4 and/or week 12. Responders are depicted in 
green, nonresponders in red. (C) Correlation plot of percentage change in MxA expression from baseline 
and percentage CLASI-A score change from baseline for all patients (placebo treated, circles; BIIB059 
treated, triangles). (D) CLASI-A response over time; CLASI-A responders are depicted in green, nonre-
sponders in red. *Subject 1 initiated steroid treatment during the study. ACLE, acute CLE; DLE, discoid 
lupus erythematosus; ND, not determined; NR, no response; R, response; SCLE, subacute CLE.
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with active skin disease, the lower serum concentration observed 
in patients with SLE compared with HV may be due to the bind-
ing of BIIB059 on pDCs accumulated in active skin lesions and, 
potentially, other tissues.
Previous in vitro studies indicated that BIIB059 binding to 
BDCA2 results in its rapid internalization from the cell surface of 
human pDCs, colocalization of the BIIB059/BDCA2 complex in 
the endolysosomal compartment that is known to be critical for 
TLR7/9 signaling, and inhibition of IFN-I production (28, 30–34). 
These observations were recapitulated in cynomolgus monkeys, 
where a single dose of BIIB059 led to BDCA2 internalization and 
corresponding functional inhibition of cynomolgus pDCs in vivo 
(28). In this clinical study, the determination of BDCA2 receptor 
levels on the pDC cell surface was therefore used to inform on 
both target engagement and PD response. Consistent with the 
preclinical findings, BIIB059 treatment led to a rapid and sharp 
decrease of BDCA2 levels on the surface of pDCs in both HV 
and patients with SLE. BDCA2 internalization correlated with 
circulating BIIB059 levels in treated study participants, thereby 
establishing a PK/PD correlation in vivo. More specifically, the 
dose-dependent return to baseline of BDCA2 levels indicated that 
a threshold of circulating BIIB059 must be reached (~1 μg/ml), 
below which there is insufficient BIIB059 to saturate the BDCA2 
receptors and mediate internalization, resulting in BDCA2 return-
ing to the cell surface.
All the skin biomarkers assessed, namely IFN-regulated pro-
teins MxA (Figures 5 and 6) and IFITM3 (Supplemental Figure 
5B), CD45+ cellular infiltrates (Figure 6), and pDC (CD123+ cells) 
(Supplemental Figure 5D), generally demonstrated similar trends 
in response to BIIB059 treatment. Together, these data indicate 
that in some patients BIIB059 not only affects the IFN response, 
but also reduces inflammation in lesional skin.
Discussion
This first-in-human study assessed the safety, tolerability, and 
PK/PD profiles of single ascending doses of BIIB059 (0.05–20 
mg/kg) in HV and 20 mg/kg in patients with SLE and active skin 
disease. Single-dose administration of BIIB059 was well tolerat-
ed across all dose levels. Most of the AEs were mild to moderate 
in severity. One patient with SLE experienced SAEs that were not 
considered related to BIIB059 treatment. The single-dose i.v. 
PK profile of BIIB059 was characteristic of a mAb, and increas-
es in exposure were observed with increases in dose (0.05–20 
mg/kg) in HV. The absolute bioavailability of the single s.c. dose 
tested was approximately 50%. In patients with SLE, a single i.v. 
dose of 20 mg/kg resulted in lower exposure than in HV given 
the same dose. pDCs are known to be reduced in the peripher-
al blood of patients with SLE, but are increased in target organs, 
such as active lupus skin lesions or kidneys (15, 16, 19, 21–23). 
Because all patients with SLE recruited to the study presented 
Figure 6. BIIB059 normalizes MxA expression and reduces cellular infiltration in skin lesions of patients with SLE. Representative photomicrographs of 
IHC from patient 5 (A) MxA protein (also shown in Figure 5B) and (C) CD45+ cells. HV (top panel), predose patient 5 (lower left panel), week 4 after BIIB059 
treatment (lower right panel). (B and D) Percentage area of immunoreactivity of MxA protein and CD45 in placebo- and BIIB059-treated patients before 
(day –1) and 4 weeks after BIIB059 administration. Healthy range was determined using biopsies from 8 HV; dotted lines delineate the healthy range. 
Responders are depicted with a black line, nonresponders with a red line.
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in the skin of patients with SLE were observed at week 4 after 
a single administration. Biopsies were collected only at week 
4 after treatment; therefore, based on the sustained improve-
ment in CLASI-A responses in some patients (at least up to week 
12), it is possible that the BIIB059-mediated reduction in IFN-I 
response in the skin is maintained for a longer period.
Our data confirm that pDCs are the major producers of 
IFN-I in the skin of established CLE lesions (38). PDCs have 
been reported to account for up to 5%–10% of the immune infil-
trate in lesional skin of patients with SLE, where interferogenic 
immune complexes are known to be deposited, and can produce 
1000-fold more IFN than other cell types (19, 38, 39). By target-
ing BDCA2, BIIB059 was effective at inhibiting pDC-derived 
IFN-I in the skin and normalizing the IFN response in patients 
with SLE, thus confirming the biological activity of BIIB059 in 
vivo in the target organ.
In addition to affecting the IFN response, improvement in skin 
disease activity was also observed upon treatment with BIIB059. 
Notably, the same patients who demonstrated reductions in MxA 
expression were also classified as clinical responders on the basis 
of a 4-point reduction in CLASI-A score at week 4 and/or week 
12 after a single injection of BIIB059. Improvement in CLASI-A 
scores correlated with the percentage reduction in MxA expres-
sion in the skin lesions. Of note, no associations were observed 
between IRG score change in whole blood and CLASI-A score 
change in patients with SLE (data not shown). These data suggest 
that local pDC-derived IFN-I in lesional skin rather than systemic 
IFN-I may play a key role in CLE pathogenesis. In this context, in 
vivo administration of BIIB059 appears to inhibit IFN-I produc-
tion by pDCs in the skin effectively, leading to the clinical cutane-
ous benefit observed in this phase I study.
Previous preclinical studies demonstrated that BIIB059 does 
not affect pDC numbers in cynomolgus monkeys (28). Admin-
istration of BIIB059 to human subjects resulted in a transient 
decrease in circulating pDC numbers at all dose levels in both 
HV and patients with SLE. Although the main mechanism of 
action of BIIB059 is the engagement of the inhibitory receptor 
BDCA2 to dampen pDC responses, it is possible that BIIB059 
leads to Ab-mediated depletion of human pDCs owing to its 
effector-competent Fc region. However, this effect is unlikely to 
be a robust mechanism of action of BIIB059, as demonstrated 
by the rather transient effect on pDC numbers. Additionally, the 
rapid, sustained, and near-complete internalization of BIIB059 
after binding of BDCA2 would likely preclude any efficient 
Ab-mediated pDC depletion in vivo.
In addition to assessing PK, PD, safety, and tolerability, 
we sought to confirm proof of biological activity of BIIB059 in 
patients with SLE with active skin disease. On the basis of the 
mechanism of action of BIIB059, the biological activity should 
be manifested by the inhibition of pDC-derived IFN-I and con-
sequent dampening of the IFN response in whole blood and skin 
lesions in patients with SLE. Patients who received BIIB059 
demonstrated a reduction of approximately 50% in IRG expres-
sion in whole blood 24 hours after administration, confirming 
that pDCs partially contribute to systemic IFN-I activation. 
In contrast with the results in blood, BIIB059 treatment was 
very effective at normalizing IFN response proteins (MxA and 
IFITM3) in lesional skin. Normalization of MxA expression 
occurred in 5 of 6 patients with high MxA expression at base-
line upon treatment with BIIB059. None of the placebo-treated 
patients with elevated baseline MxA demonstrated normaliza-
tion of MxA expression. The effects of BIIB059 on IFN-I activity 
Figure 7. Model of BIIB059 mechanism of action in CLE. (A) In CLE, pDCs accumulate in skin lesions and produce IFN-I and IFN-λ (large arrow), as detected 
by the upregulation of the IFN-responsive protein MxA in the epidermis. pDCs also secrete a broad range of cytokines and chemokines, which in addition 
to IFN-I, may support the recruitment of inflammatory cells into the lesions (depicted by CD45+ cells). (B) Treatment with BIIB059 leads to the functional 
inhibition of pDCs and the dampening of IFN-I and likely other inflammatory mediators, resulting in decreased MxA expression, reduction in immune 
cellular infiltrates, and amelioration of disease activity in CLE lesions.
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Seven cohorts, comprising 6–9 HV each, were randomized to 
receive either i.v. (cohorts 1–6) or s.c. (cohort 7) BIIB059 or matching 
placebo in a 2:1 or 3:1 ratio (Figure 1). Cohorts 1–6 received a single i.v. 
dose of placebo or 0.05, 0.3, 1, 3, 10, or 20 mg/kg BIIB059. Cohort 
7 received a single s.c. dose of placebo or 50 mg BIIB059. The 12 
patients with SLE in cohort 8 were randomized 2:1 to receive a single 
i.v. dose of placebo (n = 4) or 20 mg/kg BIIB059 (n = 8). The study 
included a 28-day screening period, a 3-day treatment and outpatient 
observation period (dose administered on day 1), a 16-week follow-up 
period for both part 1 and part 2, and an additional 12-week extended 
follow-up period for part 2. The extended follow-up period consisted 
of telephone calls to subjects for reporting and monitoring SAEs and 
AEs of interest only.
Eligibility criteria
Eligible HV were aged 18–55 years inclusive at the time of informed 
consent, in good health as determined by the investigator, and had a 
body mass index between 18 and 30 kg/m2 and body weight of 45 kg 
or more. Eligible patients with SLE in part 2 of the study were age 18 
years or more at the time of informed consent, had an SLE diagnosis 
according to the 1997 American College of Rheumatology classifi-
cation criteria for SLE (41), had a disease duration of 6 months or 
longer, had a documented history of antinuclear Ab (titer ≥1:80) or 
anti-dsDNA Ab prior to screening, and had the presence of active 
lupus skin disease, including acute, subacute, and/or chronic cutane-
ous lupus at the time of screening and randomization. Subjects were 
also willing to have at least 2 skin biopsies of the affected skin area. 
Final CLE diagnosis was adjudicated by 2 dermatologists. No specific 
CLASI-A or SLEDAI-2K score was required at baseline. Patients with 
active lupus nephritis or active neuropsychiatric SLE were excluded 
as well as patients at high risk of infection. Stable oral prednisone (or 
equivalent) at a dose of up to 15 mg and treatment with antimalarials, 
methotrexate (maximum 20 mg/week), or azathioprine (maximum 
200 mg/day) were allowed if the dose regimen was stable for at least 
28 days prior to randomization. Other SLE standard of care medica-
tions were not allowed.
Efficacy assessment
In part 2, exploratory efficacy analyses of SLE disease activity were 
performed using the disease instruments: CLASI (36, 37) and the SLE-
DAI-2K (35).
Safety profile
Safety endpoints included AEs; AEs of interest (viral infections); 
SAEs; vital signs; 12-lead ECG; and laboratory safety assessments, 
including hematology with complete blood count with differential 
and platelet count; blood chemistry (total protein, albumin, cre-
atinine, blood urea nitrogen, uric acid bilirubin total and direct, 
alkaline phosphatase, alanine aminotransferase, aspartate trans-
aminase, γ-glutamyl transferase, glucose, calcium, phosphorus, 
bicarbonate, chloride, sodium, and potassium; urinalysis with dip-
stick for blood, protein, and glucose, microscopic examination); 
C-reactive protein; immunophenotyping; WBC count and absolute 
differential count of monocytes, neutrophils, and lymphocytes; 
quantitative immunoglobulins (IgA, IgM, and IgG); complement 
levels (C3, C4, and Ch50); vaccine titers (tetanus, diphtheria, and 
pneumococcus); and serum antibodies to BIIB059.
We also observed that CLASI-A responders with elevated base-
line CD45+ cellular infiltration in their skin lesions exhibited reduc-
tions in immune cellular infiltration upon treatment with BIIB059. 
This finding supports the hypothesis that pDCs are critical for 
maintaining the inflammatory environment in SLE skin lesions. 
BIIB059-mediated functional inhibition of pDCs was shown to 
inhibit all pDC-derived cytokines and chemokines in vitro, includ-
ing IFN-λ1 (type III IFN) (Supplemental Figure 6). Type III IFN, 
comprising IFN-λ1 (IL-29), IFN-λ2 (IL28a), and IFN-λ3 (IL-28b), 
binds to a different receptor than IFN-I, but induces a similar sig-
naling cascade and IFN response, including driving MxA expres-
sion (40). Although pDCs are not the major producers of the non–
IFN-I inflammatory mediators, accumulation of pDCs in affected 
skin could make them an appreciable source capable of supporting 
the recruitment of inflammatory cells into the lesions and amplify-
ing the IFN response (MxA) via IFN-λ in addition to IFN-I. Thus, 
the overall effect of BIIB059 on skin immune infiltration could be 
mediated by the inhibition of both pDC-derived IFN-I and proin-
flammatory mediators, including chemokines, and BIIB059 may 
provide a broad therapeutic benefit in SLE (Figure 7, A and B).
In this small phase I clinical study, 2 patients treated with 
BIIB059 were classified as nonresponders on the basis of CLA-
SI-A reduction criteria at week 4 and/or week 12. One of the 2 
nonresponders, for whom a skin biopsy was available, did not 
display reductions in IFN response or inflammatory infiltration 
in the skin. This lack of response in skin biomarkers and disease 
activity could not be explained by inadequate drug exposure. A 
multiple-dose regimen of BIIB059 and a study with a larger num-
ber of patients are needed to understand better and confirm the 
potential clinical benefit of BIIB059 in the skin, but also possibly 
in other target organs affected by lupus. In this small phase I study, 
the number of SLE patients with extracutaneous manifestations 
was extremely low, precluding any meaningful conclusions of the 
effect of BIIB059 on other systemic manifestations of the disease 
or analyses of the SLEDAI-2K. BIIB059 is currently being evaluat-
ed in a phase 2 clinical trial in patients with active SLE and patients 
with active CLE (NCT02847598).
BIIB059 is the first therapy, to our knowledge, to specifical-
ly target pDCs in patients with SLE. The primary objective of this 
first-in-human study was achieved by establishing PK/PD correla-
tions in vivo and demonstrating tolerability and a favorable safety 
profile for BIIB059. We opted for an organ-specific approach by 
studying the effects of pDC inhibition in the skin of patients with 
SLE. With the caveat that the SLE cohort had a small number of 
patients with SLE (12 total), our results highlight the central role of 
pDC-derived IFN-I in the pathogenesis of skin manifestations in 
SLE and suggest that targeting pDCs with BIIB059 is a promising 
therapy for SLE and CLE.
Methods
Study design
This study (internal sponsor study code 230LE101) was a randomized, 
multicenter, phase Ib, placebo-controlled, single ascending dose and 
multiple ascending dose trial of BIIB059 in HV (parts 1 and 3, respec-
tively) or patients with cutaneous SLE (parts 2 and 3, respectively). 
Only parts 1 and 2 are reported here.
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Real-time PCR gene-expression analysis. The expression of 37 
genes associated with IFN activity was analyzed using the BioMark 
HD System (Fluidigm). Owing to the number of assays, expression 
analysis for each sample was performed across 2 separate runs using 
independent assay panels. The first panel contained 26 assays as 
well as assays for 4 housekeeping genes (ACTB, GAPDH, UBC, and 
YWHAZ), while the second panel contained 11 assays and 3 house-
keeping gene assays (UBC, YWHAZ, and B2M). Custom TaqMan 
Expression Assays (Thermo Fisher Scientific) and samples were 
prepared according to Fluidigm recommendations and loaded into 
96.96 Dynamic Array Integrated Fluidic Circuits (IFC) (Fluidigm). 
Samples were loaded singly, and assays were loaded in triplicate. IFC 
plates were primed and loaded using the Controller HX (Fluidigm) 
and then transferred to the BioMark HD for real-time PCR data col-
lection. The following thermocycling program was used: 70°C for 30 
minutes, 25°C for 10 minutes, 95°C for 1 minute followed by 45 cycles 
of 96°C for 5 seconds and 60°C for 20 seconds.
Sample data were normalized to the mean housekeeping gene 
value for each run, and any sample with an SD greater than 0.3 Ct 
was omitted from analysis. An endogenous quality control (EQC) 
was prepared for each assay panel and used to evaluate run accep-
tance. Panel 1 EQC was prepared by combining cDNA from 4 SLE 
donors, while panel 2 EQC was prepared by combining cDNA from 
3 SLE donors and 2 Sjögren’s donors. Each EQC was preamplified 
10× and then diluted into the appropriate range for the assay. The 
performance of each EQC was evaluated over 5 independent runs, 
and acceptance criteria for each assay were set at ±0.3 ΔCt from the 
mean ΔCt of each EQC assay result.
PK methods
PK assay. The assay to quantify BIIB059 in serum samples was a 
sandwich ELISA that utilized a BIIB059 anti-idiotypic Ab as capture 
reagent and HRP-mouse antihuman IgG Fc conjugate for detection. 
Substrate (3,3′,5,5′-tetramethylbenzidine) was added to plate wells, 
and color development was subsequently stopped by the addition 
of 1N sulfuric acid. OD450 was read on a plate reader, and concentra-
tions were determined by interpolation from a standard curve using a 
5-parameter curve fit.
Dose selection and PK methods. The starting dose of 0.05 mg/kg 
(i.v. infusion) was expected to have a low pharmacological response 
based on the estimated human in vivo drug concentration that 
resulted in 10% of maximal response (EC10) for BDCA2 internaliza-
tion and the projected human observed Cmax. The mean EC10 value 
from preclinical experiments in cynomolgus monkeys was approxi-
mately 0.064 μg/ml. To account for the 2-fold higher frequency of 
pDCs in humans and 8-fold higher BDCA2 density on human pDCs 
compared with those of cynomolgus monkeys, the estimated human 
in vivo EC10 for BDCA2 internalization was approximately 1.03 μg/
ml. A BIIB059 serum concentration profile following a single 0.05 
mg/kg dose (for 70 kg body weight) via a 30-minute i.v. infusion 
was simulated and gave a projected human Cmax of approximately 
1.12 μg/ml. Because this was similar to the estimated human in vivo 
EC10 for BDCA2 internalization (1.03 μg/ml), this starting dose was 
expected to have a low pharmacological response in humans and 
therefore was the appropriate starting dose for the single ascending 
dose part of the study. Furthermore, substantial safety margins (rel-
ative to the no observed adverse effect level [NOAEL] of 125 mg/kg 
Materials
For flow cytometry, the following were used: BD FACS Lysing Solu-
tion 10× Concentrate (BD Biosciences, catalog 349202); BD Trucount 
Absolute Counting Tubes (BD Biosciences, catalog 340334); and 
quantum molecules of equivalent soluble fluorochrome (MESF) FITC 
Calibration Beads (Bangs Laboratories, catalog 555).
BIIB059 (clone 24F4A) is a fully humanized Ab produced in Chi-
nese hamster ovary cells as previously described (28). BIIB059 is sup-
plied as a sterile liquid drug product containing 50 mg/ml BIIB059, 
10 mM sodium citrate, 140 mM l-arginine hydrochloride, and 0.05% 
polysorbate-80 at pH 6.0. It is provided in 5 ml vials containing 250 
mg of BIIB059 per vial.
The following antibodies were used: mouse IgG1κ-FITC (clone 
X40, BD Biosciences, catalog 349041); anti-BDCA2-FITC (clone 
2D6, Biogen-generated mAb, ref. 28, FITC conjugation by BioLeg-
end); antihuman CD123-PE (clone 9F5, BD Biosciences, catalog 
340545); antihuman HLA-DR-PerCP (clone L243, BD Biosciences, 
catalog 347364); antihuman lineage cocktail–APC (clones UCHT1, 
HCD14, 3G8, HIB19, 2H7, HCD56, BioLegend, catalog 348803); 
mouse monoclonal anti-CD45 (clone MEM-28, Abcam, catalog 
ab8216); mouse monoclonal anti-MxA (clone M143, provided by G. 
Kochs, University Medical Center, Freiburg, Germany,); rabbit poly-
clonal anti-IFITM3 (Thermo Scientific, catalog Pa5-30382); rab-
bit monoclonal anti-CD31 (clone SP38, Spring Bioscience, catalog 
M3384); and mouse monoclonal anti-CD123 (clone 7G3, BD Biosci-
ences, catalog 554527).
BDCA2 expression and pDC count
Human whole blood (250 μl) was mixed with fluorochrome-con-
jugated Ab panels containing either anti-BDCA2 or mouse IgG1κ 
isotype control. The contents were incubated on ice and in the dark 
for 30 minutes. RBCs were lysed for 10 minutes at room tempera-
ture using 5 ml of 1× FACS Lysing Solution (BD). Isolated cells were 
washed twice with 5 ml of PBS + 1% BSA. Following wash steps, 
cells were resuspended in 500 μl of PBS + 1% BSA and transferred 
to BD Trucount Absolute Counting Tubes. Sample acquisition was 
performed on a BD FACSCalibur flow cytometer (BD Biosciences). 
For the purpose of standardizing fluorescence intensity, Quan-
tum MESF FITC Calibration Beads (Bangs Laboratories) were 
also acquired under the same instrument gain settings at the time 
of sample acquisition. BDCA2 expression on the pDC population 
(CD123+ HLA-DR+) was expressed as an MESF value. The absolute 
number of pDCs (cells/μl) was determined by comparing cellular 
events with the known number of fluorescent beads present in the 
BD Trucount Absolute Counting Tubes.
Ab cocktail panels. Ab cocktail panels were as follows: mouse 
IgG1κ-FITC or BDCA2-FITC CD123-PE HLA-DR-PerCP; lineage 
cocktail (CD3, CD14, CD16, CD19, CD20, CD56)-APC.
IFN signature assays
RNA isolation and reverse transcription. Blood was collected in PAXgene 
Blood RNA Tubes (BD Biosciences) and stored at –20°C until ready for 
use. Intracellular RNA was isolated using the PAXgene Blood RNA Kit 
(BD Biosciences) and quantified using a NanoDrop spectrophotome-
ter (Thermo Fisher Scientific). RNA was normalized to 20 ng/ml and 
then reverse transcribed using a High Capacity cDNA Reverse Tran-
scription Kit (Thermo Fisher Scientific).
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lots, and IHC and image analysis protocols used on HV specimens were 
matched, and assay variation for epidermal MxA protein was found to 
be 7%, well within the accepted variation range for this assay.
For further information, see Supplemental Methods.
Statistics
The safety analysis set included all the subjects who were random-
ized and received at least 1 dose of BIIB059 or placebo. The PD anal-
ysis set included all the subjects who were randomized and received 
at least 1 dose of BIIB059 or placebo and had at least 1 sample bio-
marker or other data collected after BIIB059 administration. The 
PK analysis set included all individuals in the safety analysis set 
for whom at least 1 primary PK parameter could be calculated. The 
study was not powered for any formal testing, but the sample size of 
this study was considered sufficient to characterize the single-dose 
and multiple-dose safety, tolerability, and PK and PD profiles of 
BIIB059. The association between log2 fold change of MxA and per-
centage change of CLASI-A was assessed by Spearman’s correlation. 
No formal hypothesis testing was performed. The upper limit of the 
normal range was determined by taking the maximum percentage 
area immunoreactivity in a skin compartment for the HV cohort 
rounded to the nearest 0.1%.
Study approval
Informed consent was obtained from all subjects in accordance with 
the human subjects institutional review boards of all the participating 
centers. The study was performed in accordance with the Declaration 
of Helsinki and the International Conference on Harmonization Note 
for Guidance on Good Clinical Practice (ICH Topic E6, 1996).
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i.v. in cynomolgus monkey) of approximately 1000- to 3600-fold 
were expected with this starting dose.
The planned maximum dose in parts 1 and 2 was a 20 mg/kg i.v. 
infusion. This dose was selected to ensure adequate characterization 
of the safety and tolerability of single ascending doses of BIIB059 with 
the aim of identifying the maximum tolerated dose, if feasible. Based 
on the projected Cmax and AUC∞, the safety margins for this planned 
maximum dose (relative to the NOAEL of 125 mg/kg i.v.) were approx-
imately 2.5- to 9-fold.
A fixed s.c. dose (50 mg at a concentration of 50 mg/ml) rather 
than a body weight–based s.c. dose was chosen to minimize the vari-
ability in the injection volume of BIIB059.
PK parameter estimation method. All subjects with observed PK con-
centrations sufficient for estimating the PK parameters were included 
in the PK analyses. PK parameters for BIIB059 were estimated on 
the basis of standard noncompartmental methods using the Phoenix 
version 6.2 (Certara Corp.) software package. The Cmax and tmax were 
determined directly from the plasma concentration-time profile for 
BIIB059. The terminal phase elimination rate constant (λz) was estimat-
ed by log-linear regression of concentration-time data in the terminal 
portion of the PK profiles. The t1/2 was estimated as ln(2)/λz. The AUC 
from zero time to last observed time point (AUCt) was calculated using 
the trapezoidal rule. The AUC extrapolated from the last data point to 
infinity (AUCt-∞) was estimated by dividing the concentration at the last 
point by the elimination rate constant (λz). The total AUC (AUC∞) was 
calculated as AUCt + AUCt-∞. The clearance (CL) and volume of distri-
bution (Vz) were calculated as CL = dose/AUC∞ and Vz = (CL)/λz (for s.c. 
dosing, it is estimated as CL/F and Vz/F). The relative bioavailability 
was estimated by comparing the AUC values following administration 
of single i.v. (1 mg/kg) and s.c. (50 mg) doses of BIIB059.
IHC methods
Punch biopsies of 4 to 6 mm in formalin from affected skin were 
received from the 12 patients with SLE. Biopsies were examined and 
bisected by a pathologist, then processed into paraffin blocks. H&E-
stained sections at various intervals were examined to ensure that 
IHC was performed on sections within lesions. Punch biopsies of 4 
mm were collected from sun-exposed skin of HVs matched approxi-
mately by age and ethnicity to the BIIB059-treated cohort (mean age 
= 34; range, 28–37; White, 6/8; Asian, 1/8; Black or African American, 
1/8; female, 8/8) by Folio Biosciences, then processed into paraffin 
blocks for transfer to Biogen. IHC for MxA, IFITM3, CD45, and dual 
IHC for CD123/CD31 were performed on 1 section from each speci-
men on Ventana Discovery Ultra or Ventana Discovery XT automated 
staining instruments.
Slides were digitized with a Panoramic P250 scanner at ×200 reso-
lution, and skin biopsies were hand annotated to define epidermis, pap-
illary dermis, and reticular dermis; follicular epithelium and adnexa 
were included with epidermis, and sebaceous glands were excluded. 
Using a combination of color deconvolution and median filters, cus-
tomized image analysis algorithms were generated in Visiopharm to 
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